Search

Your search keyword '"Leiby, Benjamin E"' showing total 643 results
Start Over Author "Leiby, Benjamin E"
643 results on '"Leiby, Benjamin E"'

1. Sensory Phenotypes in Autism: Making a Case for the Inclusion of Sensory Integration Functions

Author

Schaaf, Roseann C., Mailloux, Zoe, Ridgway, Elizabeth, Berruti, Alaina S., Dumont, Rachel L., Jones, Emily A., and Leiby, Benjamin E.

Subjects
Pervasive developmental disorders -- Diagnosis -- Care and treatment, Phenotype -- Analysis
Abstract

Sensory features are part of the diagnostic criteria for autism and include sensory hypo/hyper reactivity and unusual sensory interest; however, additional sensory differences, namely differences in sensory integration, have not been routinely explored. This study characterized sensory integration differences in a cohort of children (n = 93) with a confirmed diagnosis of autism (5-9 years) using a standardized, norm-referenced battery. Mean z scores, autism diagnostic scores, and IQ are reported. Participants showed substantial deficits in tactile perception, praxis, balance, visual perception, and visual-motor skills. Relationship with autism diagnostic test scores were weak or absent. Findings suggest additional sensory difficulties that are not typically assessed or considered when characterizing sensory features in autism. These data have implications for a greater understanding of the sensory features in the autism phenotype and the development of personalized treatments., Author(s): Roseann C. Schaaf [sup.1] , Zoe Mailloux [sup.1] , Elizabeth Ridgway [sup.2] , Alaina S. Berruti [sup.3] , Rachel L. Dumont [sup.1] , Emily A. Jones [sup.4] , Benjamin [...]

Published
2023
Full Text
View/download PDF

3. RAPIDIRON Trial follow-up study — the RAPIDIRON-KIDS Study: protocol of a prospective observational follow-up study

Author

Derman, Richard J., Bellad, Roopa B., Bellad, Mrutyunjaya B., Bradford-Rogers, Jesse, Georgieff, Michael K., Aghai, Zubair H., Thind, Simal, Auerbach, Michael, Boelig, Rupsa, Leiby, Benjamin E., Short, Vanessa, Yogeshkumar, S., Charantimath, Umesh S., Somannavar, Manjunath S., Mallapur, Ashalata A., Pol, Ramesh, Ramadurg, Umesh, Sangavi, Radha, Peerapur, Basavaraj V., Banu, Nasima, Patil, Praveen S., Patil, Amaresh P., Roy, Subarna, Vastrad, Phaniraj, Wallace, Dennis, Shah, Hemang, and Goudar, Shivaprasad S.

Published
2023
Full Text
View/download PDF

7. Age Suppresses the Association Between Traumatic Brain Injury Severity and Functional Outcomes: A Study Using the NIDILRR TBIMS Dataset.

Author

Winter, Laraine, Moriarty, Helene, Robinson, Keith M., Leiby, Benjamin E., Schmidt, Krista, Whitehouse, Christina R., and Swanson, Randel L.

Abstract

Objectives: Recovery from traumatic brain injury (TBI) is extremely difficult to predict, with TBI severity usually demonstrating weak predictive validity for functional or other outcomes. A possible explanation may lie in the statistical phenomenon called suppression, according to which a third variable masks the true association between predictor and outcome, making it appear weaker than it actually is. Age at injury is a strong candidate as a suppressor because of its well-established main and moderating effects on TBI outcomes. We tested age at injury as a possible suppressor in the predictive chain of effects between TBI severity and functional disability, up to 10 years post-TBI. Setting: Follow-up interviews were conducted during telephone interviews. Participants: We used data from the 2020 NDILRR Model Systems National Dataset for 4 successive follow-up interviews: year 1 (n = 10,734), year 2 (n = 9174), year 5 (n = 6,201), and year 10 (n = 3027). Design: Successive cross-sectional multiple regression analyses. Main Measures: Injury severity was operationalized using a categorical variable representing duration of posttrauma amnesia. The Glasgow Outcomes Scale--Extended (GOS-E) operationally defined functioning. Sociodemographic characteristics having significant bivariate correlations with GOS-E were included. Results: Entry of age at injury into the regression models significantly increases the association between TBI severity and functioning up to 10 years post-TBI. Conclusions: Age at injury is a suppressor variable, masking the true effect of injury severity on functional outcomes. Identifying the mediators of this suppression effect is an important direction for TBI rehabilitation research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Phase 2A trial of Ad5.F35-GUCY2C-PADRE vaccine for recurrence prevention in gastrointestinal (GI) adenocarcinomas post definitive surgery and adjuvant therapies.

Author

Bashir, Babar, primary, Mitchell, Edith P., additional, Posey, James, additional, Basu Mallick, Atrayee, additional, Lin, Daniel, additional, Singla, Rajan, additional, Fernandez, Eduardo, additional, Ramirez, Michael J., additional, Singh, Jagmohan, additional, Kraft, Walter K., additional, Crutcher, Madison, additional, Lefler, Daniel S., additional, Leiby, Benjamin E., additional, Zhan, Tingting, additional, Waldman, Scott A., additional, and Snook, Adam E., additional

Published
2024
Full Text
View/download PDF

17. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma

Author

Ponzini, Francesca M, primary, Schultz, Christopher W, additional, Leiby, Benjamin E, additional, Cannaday, Shawnna, additional, Yeo, T, additional, Posey, James, additional, Bowne, Wilbur B, additional, Yeo, Charles, additional, Brody, Jonathan R, additional, Lavu, Harish, additional, and Nevler, Avinoam, additional

Published
2023
Full Text
View/download PDF

21. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer

Author

Lin, Jianqing, Song, Andrew J., Hoffman-Censits, Jean, Leiby, Benjamin E., Tuluc, Madalina, Shaw, Colette, Harshyne, Larry, Kean, Rhonda, Bar-Ad, Voichita, Den, Robert B., Hurwitz, Mark D., Louie, Jennifer, Philipose, Sherin, Deshmukh, Sandeep P., Johnson, Jennifer M., Dicker, Adam P., Hooper, Douglas C., Kelly, William K., and Lu, Bo

Published
2020
Full Text
View/download PDF

24. Hawks and Doves: Perceptions and Reality of Faculty Evaluations

Author

Zavodnick, Jillian, Doroshow, Jonathan, Rosenberg, Sarah, Banks, Joshua, Leiby, Benjamin E., Mingioni, Nina, Zavodnick, Jillian, Doroshow, Jonathan, Rosenberg, Sarah, Banks, Joshua, Leiby, Benjamin E., and Mingioni, Nina

Abstract

OBJECTIVES: Internal medicine clerkship grades are important for residency selection, but inconsistencies between evaluator ratings threaten their ability to accurately represent student performance and perceived fairness. Clerkship grading committees are recommended as best practice, but the mechanisms by which they promote accuracy and fairness are not certain. The ability of a committee to reliably assess and account for grading stringency of individual evaluators has not been previously studied. METHODS: This is a retrospective analysis of evaluations completed by faculty considered to be stringent, lenient, or neutral graders by members of a grading committee of a single medical college. Faculty evaluations were assessed for differences in ratings on individual skills and recommendations for final grade between perceived stringency categories. Logistic regression was used to determine if actual assigned ratings varied based on perceived faculty's grading stringency category. RESULTS: "Easy graders" consistently had the highest probability of awarding an above-average rating, and "hard graders" consistently had the lowest probability of awarding an above-average rating, though this finding only reached statistical significance only for 2 of 8 questions on the evaluation form ( CONCLUSIONS: Perceived differences in faculty grading stringency have basis in reality for clerkship evaluation elements. However, final grades recommended by faculty perceived as "stringent" or "lenient" did not differ. Perceptions of "hawks" and "doves" are not just lore but may not have implications for students' final grades. Continued research to describe the "hawk and dove effect" will be crucial to enable assessment of local grading variation and empower local educational leadership to correct, but not overcorrect, for this effect to maintain fairness in student evaluations.

Published
2023

25. Repurposing the FDA-Approved Anthelmintic Pyrvinium Pamoate for Pancreatic Cancer Treatment: Study Protocol for a Phase I Clinical Trial in Early-Stage Pancreatic Ductal Adenocarcinoma

Author

Ponzini, Francesca M., Schultz, Christopher W., Leiby, Benjamin E., Cannaday, Shawnna, Yeo, T., Posey, James, Bowne, Wilbur B., Yeo, Charles, Brody, Jonathan R., Lavu, Harish, Nevler, Avinoam, Ponzini, Francesca M., Schultz, Christopher W., Leiby, Benjamin E., Cannaday, Shawnna, Yeo, T., Posey, James, Bowne, Wilbur B., Yeo, Charles, Brody, Jonathan R., Lavu, Harish, and Nevler, Avinoam

Abstract

BACKGROUND: Recent reports of the utilisation of pyrvinium pamoate (PP), an FDA-approved anti-helminth, have shown that it inhibits pancreatic ductal adenocarcinoma (PDAC) cell growth and proliferation in-vitro and in-vivo in preclinical models. Here, we report about an ongoing phase I open-label, single-arm, dose escalation clinical trial to determine the safety and tolerability of PP in PDAC surgical candidates. METHODS AND ANALYSIS: In a 3+3 dose design, PP is initiated 3 days prior to surgery. The first three patients will be treated with the initial dose of PP at 5 mg/kg orally for 3 days prior to surgery. Dose doubling will be continued to a reach a maximum of 20 mg/kg orally for 3 days, if the previous two dosages (5 mg/kg and 10 mg/kg) were tolerated. Dose-limiting toxicity grade≥3 is used as the primary endpoint. The pharmacokinetic and pharmacodynamic (PK/PD) profile of PP and bioavailability in humans will be used as the secondary objective. Each participant will be monitored weekly for a total of 30 days from the final dose of PP for any side effects. The purpose of this clinical trial is to examine whether PP is safe and tolerable in patients with pancreatic cancer, as well as assess the drug's PK/PD profile in plasma and fatty tissue. Potential implications include the utilisation of PP in a synergistic manner with chemotherapeutics for the treatment of pancreatic cancer. ETHICS AND DISSEMINATION: This study was approved by the Thomas Jefferson Institutional Review Board. The protocol number for this study is 20F.041 (Version 3.1 as of 27 October 2021). The data collected and analysed from this study will be used to present at local and national conferences, as well as, written into peer-reviewed manuscript publications. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT05055323.

Published
2023

28. Autonomic Dysregulation during Sensory Stimulation in Children with Autism Spectrum Disorder

Author

Schaaf, Roseann C., Benevides, Teal W., and Leiby, Benjamin E.

Abstract

Autonomic nervous system (ANS) activity during sensory stimulation was measured in 59 children with autism spectrum disorder (ASD) ages 6-9 in comparison to 30 typically developing controls. Multivariate comparisons revealed significant differences between groups in the respiratory sinus arrhythmia (parasympathetic measure) vector of means across sensory stimuli (p = 0.02) and in change from domain to domain (p = 0.01). Sympathetic activity, measured by pre-ejection period, did not differ significantly between groups, although it was higher in ASD participants. Findings suggest that participants with ASD demonstrated a different pattern of parasympathetic activity during sensory stimulation. Findings are discussed in relation to the biological mechanisms of sensory processing in autism, insight into the autism phenotype, and the utility of ANS activity as an outcomes marker.

Published
2015
Full Text
View/download PDF

31. Figure S3 from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

Author

Nevler, Avinoam, primary, Muller, Alexander J., primary, Sutanto-Ward, Erika, primary, DuHadaway, James B., primary, Nagatomo, Kei, primary, Londin, Eric, primary, O'Hayer, Kevin, primary, Cozzitorto, Joseph A., primary, Lavu, Harish, primary, Yeo, Theresa P., primary, Curtis, Mark, primary, Villatoro, Tatiana, primary, Leiby, Benjamin E., primary, Mandik-Nayak, Laura, primary, Winter, Jordan M., primary, Yeo, Charles J., primary, Prendergast, George C., primary, and Brody, Jonathan R., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure from Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma

Author

Luginbuhl, Adam J., primary, Johnson, Jennifer M., primary, Harshyne, Larry A., primary, Linnenbach, Alban J., primary, Shukla, Sanket K., primary, Alnemri, Angela, primary, Kumar, Gaurav, primary, Cognetti, David M., primary, Curry, Joseph M., primary, Kotlov, Nikita, primary, Antysheva, Zoya, primary, Degryse, Sandrine, primary, Mannion, Kyle, primary, Gibson, Michael K., primary, Netterville, James, primary, Brown, Brandee, primary, Axelrod, Rita, primary, Zinner, Ralph, primary, Tuluc, Madalina, primary, Gargano, Stacey, primary, Leiby, Benjamin E., primary, Shimada, Ayako, primary, Mahoney, My G., primary, Martinez-Outschoorn, Ubaldo, primary, Rodeck, Ulrich, primary, Kim, Young J., primary, South, Andrew P., primary, and Argiris, Athanassios, primary

Published
2023
Full Text
View/download PDF

33. Supplemental legend from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

Author

Nevler, Avinoam, primary, Muller, Alexander J., primary, Sutanto-Ward, Erika, primary, DuHadaway, James B., primary, Nagatomo, Kei, primary, Londin, Eric, primary, O'Hayer, Kevin, primary, Cozzitorto, Joseph A., primary, Lavu, Harish, primary, Yeo, Theresa P., primary, Curtis, Mark, primary, Villatoro, Tatiana, primary, Leiby, Benjamin E., primary, Mandik-Nayak, Laura, primary, Winter, Jordan M., primary, Yeo, Charles J., primary, Prendergast, George C., primary, and Brody, Jonathan R., primary

Published
2023
Full Text
View/download PDF

34. Supplemental Tables from Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers

Author

Nevler, Avinoam, primary, Muller, Alexander J., primary, Sutanto-Ward, Erika, primary, DuHadaway, James B., primary, Nagatomo, Kei, primary, Londin, Eric, primary, O'Hayer, Kevin, primary, Cozzitorto, Joseph A., primary, Lavu, Harish, primary, Yeo, Theresa P., primary, Curtis, Mark, primary, Villatoro, Tatiana, primary, Leiby, Benjamin E., primary, Mandik-Nayak, Laura, primary, Winter, Jordan M., primary, Yeo, Charles J., primary, Prendergast, George C., primary, and Brody, Jonathan R., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Tables from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

37. Data from Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies

Author

Dylgjeri, Emanuela, primary, McNair, Christopher, primary, Goodwin, Jonathan F., primary, Raymon, Heather K., primary, McCue, Peter A., primary, Shafi, Ayesha A., primary, Leiby, Benjamin E., primary, de Leeuw, Renée, primary, Kothari, Vishal, primary, McCann, Jennifer J., primary, Mandigo, Amy C., primary, Chand, Saswati N., primary, Schiewer, Matthew J., primary, Brand, Lucas J., primary, Vasilevskaya, Irina, primary, Gordon, Nicolas, primary, Laufer, Talya S., primary, Gomella, Leonard G., primary, Lallas, Costas D., primary, Trabulsi, Edouard J., primary, Feng, Felix Y., primary, Filvaroff, Ellen H., primary, Hege, Kristin, primary, Rathkopf, Dana, primary, and Knudsen, Karen E., primary

Published
2023
Full Text
View/download PDF

43. Communicating Diagnostic Uncertainty at Emergency Department Discharge: A Simulation-Based Mastery Learning Randomized Trial

Author

Rising, Kristin L., primary, Cameron, Kenzie A., additional, Salzman, David H., additional, Papanagnou, Dimitrios, additional, Doty, Amanda M.B., additional, Piserchia, Katherine, additional, Leiby, Benjamin E., additional, Shimada, Ayako, additional, McGaghie, William C., additional, Powell, Rhea E., additional, Klein, Matthew R., additional, Zhang, Xiao Chi, additional, Vozenilek, John, additional, and McCarthy, Danielle M., additional

Published
2022
Full Text
View/download PDF

47. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial

Author

Tatarian, Talar, Jiang, Wei, Leiby, Benjamin E., Grigoli, Amanda, Jimbo, Masaya, Dabbish, Nooreen, Neoptolemos, John P., Greenhalf, William, Costello, Eithne, Ghaneh, Paula, Halloran, Christopher, Palmer, Daniel, Buchler, Markus, Yeo, Charles J., Winter, Jordan M., and Brody, Jonathan R.

Published
2018
Full Text
View/download PDF

48. PARP‐1 regulates DNA repair factor availability

Author

Schiewer, Matthew J, Mandigo, Amy C, Gordon, Nicolas, Huang, Fangjin, Gaur, Sanchaika, de Leeuw, Renée, Zhao, Shuang G, Evans, Joseph, Han, Sumin, Parsons, Theodore, Birbe, Ruth, McCue, Peter, McNair, Christopher, Chand, Saswati N, Cendon‐Florez, Ylenia, Gallagher, Peter, McCann, Jennifer J, Poudel Neupane, Neermala, Shafi, Ayesha A, Dylgjeri, Emanuela, Brand, Lucas J, Visakorpi, Tapio, Raj, Ganesh V, Lallas, Costas D, Trabulsi, Edouard J, Gomella, Leonard G, Dicker, Adam P, Kelly, Wm. Kevin, Leiby, Benjamin E, Knudsen, Beatrice, Feng, Felix Y, and Knudsen, Karen E

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results